JP2022116008A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022116008A5 JP2022116008A5 JP2022077425A JP2022077425A JP2022116008A5 JP 2022116008 A5 JP2022116008 A5 JP 2022116008A5 JP 2022077425 A JP2022077425 A JP 2022077425A JP 2022077425 A JP2022077425 A JP 2022077425A JP 2022116008 A5 JP2022116008 A5 JP 2022116008A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- pharmaceutically acceptable
- cardiomyopathy
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000031229 Cardiomyopathies Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 201000005943 Barth syndrome Diseases 0.000 claims 3
- 101000835595 Homo sapiens Tafazzin Proteins 0.000 claims 3
- 102100026508 Tafazzin Human genes 0.000 claims 3
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 239000002327 cardiovascular agent Substances 0.000 claims 2
- 229940125692 cardiovascular agent Drugs 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 241000208011 Digitalis Species 0.000 claims 1
- 102000003938 Thromboxane Receptors Human genes 0.000 claims 1
- 108090000300 Thromboxane Receptors Proteins 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 239000004004 anti-anginal agent Substances 0.000 claims 1
- 229940124345 antianginal agent Drugs 0.000 claims 1
- 239000003416 antiarrhythmic agent Substances 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 239000002368 cardiac glycoside Substances 0.000 claims 1
- 229940097217 cardiac glycoside Drugs 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 239000003527 fibrinolytic agent Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000002516 radical scavenger Substances 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 238000007634 remodeling Methods 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- 230000001624 sedative effect Effects 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 229930002534 steroid glycoside Natural products 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000002889 sympathetic effect Effects 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 claims 1
- 229960000103 thrombolytic agent Drugs 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 229940124549 vasodilator Drugs 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361771534P | 2013-03-01 | 2013-03-01 | |
| US201361771642P | 2013-03-01 | 2013-03-01 | |
| US61/771,642 | 2013-03-01 | ||
| US61/771,534 | 2013-03-01 | ||
| US201361839753P | 2013-06-26 | 2013-06-26 | |
| US61/839,753 | 2013-06-26 | ||
| JP2019080101A JP6918046B2 (ja) | 2013-03-01 | 2019-04-19 | バース症候群の予防または治療のための方法及び組成物 |
| JP2021019903A JP7072692B2 (ja) | 2013-03-01 | 2021-02-10 | バース症候群の予防または治療のための方法及び組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021019903A Division JP7072692B2 (ja) | 2013-03-01 | 2021-02-10 | バース症候群の予防または治療のための方法及び組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022116008A JP2022116008A (ja) | 2022-08-09 |
| JP2022116008A5 true JP2022116008A5 (https=) | 2023-03-03 |
| JP7381652B2 JP7381652B2 (ja) | 2023-11-15 |
Family
ID=51428869
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015560377A Active JP6518197B2 (ja) | 2013-03-01 | 2014-02-28 | バース症候群の予防または治療のための方法及び組成物 |
| JP2019080101A Active JP6918046B2 (ja) | 2013-03-01 | 2019-04-19 | バース症候群の予防または治療のための方法及び組成物 |
| JP2021019903A Active JP7072692B2 (ja) | 2013-03-01 | 2021-02-10 | バース症候群の予防または治療のための方法及び組成物 |
| JP2022077425A Active JP7381652B2 (ja) | 2013-03-01 | 2022-05-10 | バース症候群の予防または治療のための方法及び組成物 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015560377A Active JP6518197B2 (ja) | 2013-03-01 | 2014-02-28 | バース症候群の予防または治療のための方法及び組成物 |
| JP2019080101A Active JP6918046B2 (ja) | 2013-03-01 | 2019-04-19 | バース症候群の予防または治療のための方法及び組成物 |
| JP2021019903A Active JP7072692B2 (ja) | 2013-03-01 | 2021-02-10 | バース症候群の予防または治療のための方法及び組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US9687519B2 (https=) |
| EP (2) | EP3626252A1 (https=) |
| JP (4) | JP6518197B2 (https=) |
| CN (3) | CN115990242A (https=) |
| CA (1) | CA2916880C (https=) |
| DK (1) | DK2961420T3 (https=) |
| ES (1) | ES2750258T3 (https=) |
| HU (1) | HUE046924T2 (https=) |
| WO (1) | WO2014134554A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2788013A4 (en) * | 2011-12-09 | 2015-08-19 | Stealth Peptides Int Inc | AROMATIC-CATIONIC PEPTIDES AND USES THEREOF |
| ES2755134T3 (es) | 2013-03-01 | 2020-04-21 | Stealth Biotherapeutics Corp | Métodos para el tratamiento de enfermedad mitocondrial |
| US9687519B2 (en) * | 2013-03-01 | 2017-06-27 | Stealth Biotherapeutics Corp | Methods and compositions for the prevention or treatment of barth syndrome |
| CA2916977A1 (en) | 2013-06-26 | 2014-12-31 | Stealth Biotherapeutics Corp | Methods and compositions for detecting and diagnosing diseases and conditions |
| US9550981B2 (en) | 2014-01-22 | 2017-01-24 | University Of Washington | Modified tafazzin proteins and methods of making and using the same |
| WO2016094791A1 (en) * | 2014-12-12 | 2016-06-16 | University Of Washington | Methods for treating and preventing cardiomyopathy |
| WO2018104172A1 (en) | 2016-12-06 | 2018-06-14 | Centre National De La Recherche Scientifique (Cnrs) | Compounds for treating barth syndrome |
| US11034724B2 (en) | 2017-04-05 | 2021-06-15 | Stealth Biotherapeutics Corp. | Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2 |
| US10676506B2 (en) | 2018-01-26 | 2020-06-09 | Stealth Biotherapeutics Corp. | Crystalline bis- and tris-hydrochloride salt of elamipretide |
| US12252554B2 (en) | 2018-12-18 | 2025-03-18 | Stealth Biotherapeutics Inc. | Analogs that target mitochondrial diseases |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
| CA2495021A1 (en) | 2001-08-06 | 2003-07-03 | Vanderbilt University | System and methods for measuring at least one metabolic rate of a plurality of cells |
| BRPI0105509B8 (pt) | 2001-11-05 | 2021-05-25 | Univ Minas Gerais | formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga |
| EP1599216B9 (en) | 2003-02-04 | 2015-02-11 | Cornell Research Foundation, Inc. | Methods for preventing mitochondrial permeability transition |
| CN101440124B (zh) | 2003-02-04 | 2012-07-18 | 科内尔研究基金会 | 用于防止线粒体通透性改变的方法 |
| WO2004069866A1 (en) * | 2003-02-10 | 2004-08-19 | Autogen Research Pty Ltd | Therapeutic molecules |
| WO2005023274A1 (en) | 2003-09-05 | 2005-03-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium |
| CA3024434A1 (en) * | 2004-01-23 | 2005-08-11 | Cornell Research Foundation, Inc. | Methods for reducing oxidative damage |
| US8500720B2 (en) | 2005-05-09 | 2013-08-06 | Medtronic, Inc | Method and apparatus for treatment of cardiac disorders |
| US20070265216A1 (en) * | 2005-10-05 | 2007-11-15 | Gross Richard W | Enhanced medical treatment in diabetic cardiomyopathy |
| WO2007121479A2 (en) * | 2006-04-18 | 2007-10-25 | Cortendo Invest, Ab | Methods and compositions for treating barth syndrome, cardiomyopathy, mitochondrial diseases and other conditions |
| US9603872B2 (en) | 2007-05-02 | 2017-03-28 | The McLeon Hospital Corporation | Methods and compositions for mitochondrial replacement therapy |
| US20080318909A1 (en) | 2007-06-14 | 2008-12-25 | Sparagna Genevieve C | Use Of Linoleic Compounds Against Heart Failure |
| WO2008156654A2 (en) | 2007-06-15 | 2008-12-24 | Massachusetts Institute Of Technology | Cytoskeleton modulators for treating metabolic disorders |
| EP3741381B1 (en) | 2008-02-26 | 2024-04-24 | Cornell University | A peptide for use for prevention and treatment of acute renal injury |
| WO2009149307A2 (en) | 2008-06-04 | 2009-12-10 | San Diego State University Research Foundation | Compositions and methods for restoring mitochondrial electron transfer function |
| AU2009280021B2 (en) | 2008-08-07 | 2012-10-04 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal |
| US20100331265A1 (en) | 2009-03-20 | 2010-12-30 | Tompkins Ronald G | Methods for the prevention and treatment of burn injuries and secondary complications |
| WO2010121268A2 (en) | 2009-04-17 | 2010-10-21 | The Salk Institute For Biological Studies | Regulation of aging by modulation of mitochondrial function |
| WO2010132347A2 (en) | 2009-05-11 | 2010-11-18 | University Of Maryland, Baltimore | Docosahexaenoic acid for the treatment of heart failure |
| WO2011019809A1 (en) | 2009-08-12 | 2011-02-17 | Cornell University | Methods for preventing or treating metabolic syndrome |
| ES2964555T3 (es) * | 2009-08-24 | 2024-04-08 | Stealth Biotherapeutics Inc | Péptido para uso en la prevención o tratamiento de la degeneración macular |
| WO2011044044A1 (en) * | 2009-10-05 | 2011-04-14 | Cornell University | Methods for the prevention or treatment of heart failure |
| EP3090754A1 (en) * | 2009-12-31 | 2016-11-09 | Stealth Peptides International, Inc. | Methods for the prevention or treatment of vessel occlusion injury |
| US20110172312A1 (en) | 2009-12-31 | 2011-07-14 | Miller Guy M | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
| US8719939B2 (en) | 2009-12-31 | 2014-05-06 | Mcafee, Inc. | Malware detection via reputation system |
| JP4643749B1 (ja) | 2010-02-03 | 2011-03-02 | 昭和電工株式会社 | 表面被覆サーメット部材の耐酸化膜形成用の処理液 |
| JP2013521231A (ja) | 2010-02-26 | 2013-06-10 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション インコーポレイテッド | ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する |
| EP3375449A1 (en) * | 2010-03-15 | 2018-09-19 | Stealth Peptides International, Inc. | Combination therapies using cyclosporine and aromatic cationic peptides |
| EP3290433A1 (en) * | 2010-05-03 | 2018-03-07 | Stealth Peptides International, Inc. | Aromatic-cationic peptides and uses of same |
| WO2012009171A2 (en) | 2010-07-15 | 2012-01-19 | The Schepens Eye Research Institute, Inc. | Compositions and methods of treatment of corneal endothelium disorders |
| SG187744A1 (en) | 2010-08-06 | 2013-03-28 | Edison Pharmaceuticals Inc | Treatment of mitochondrial diseases with naphthoquinones |
| WO2012019032A1 (en) | 2010-08-06 | 2012-02-09 | Ampere Life Sciences, Inc. | Treatment of mitochondrial diseases with vitamin k |
| US9241933B2 (en) | 2011-03-01 | 2016-01-26 | Pharnext | Compositions for treating amyotrophic lateral sclerosis |
| EP3108975A1 (en) * | 2011-03-24 | 2016-12-28 | Cornell University | Aromatic-cationic peptides and uses of same |
| CN106913860A (zh) | 2011-09-29 | 2017-07-04 | 梅约医学教育与研究基金会 | 芳族阳离子肽和使用它们的方法 |
| HK1201443A1 (en) | 2011-10-17 | 2015-09-04 | Cornell University | Aromatic-cationic peptides and uses of same |
| CA2938661A1 (en) * | 2011-10-21 | 2013-04-25 | Stemgenics, Inc | Functionalized nanoparticles for intracellular delivery of biologically active molecules |
| CN104244964A (zh) | 2012-02-22 | 2014-12-24 | 康肽德生物医药技术有限公司 | 用于预防或治疗眼科病状的方法和组合物 |
| CN104203262A (zh) * | 2012-02-23 | 2014-12-10 | 康奈尔大学 | 芳香族阳离子肽及其用途 |
| WO2014059029A1 (en) | 2012-10-09 | 2014-04-17 | President And Fellows Of Harvard College | Treatment of age-related and mitochondrial diseases by inhibition of hif-1 alpha function |
| AU2013334788A1 (en) | 2012-10-22 | 2015-06-04 | Henry Ford Health Systems | Methods for reducing risks associated with heart failure and factors associated therewith |
| US9687519B2 (en) | 2013-03-01 | 2017-06-27 | Stealth Biotherapeutics Corp | Methods and compositions for the prevention or treatment of barth syndrome |
| ES2755134T3 (es) | 2013-03-01 | 2020-04-21 | Stealth Biotherapeutics Corp | Métodos para el tratamiento de enfermedad mitocondrial |
| CA2916977A1 (en) * | 2013-06-26 | 2014-12-31 | Stealth Biotherapeutics Corp | Methods and compositions for detecting and diagnosing diseases and conditions |
-
2014
- 2014-02-28 US US14/771,408 patent/US9687519B2/en active Active
- 2014-02-28 CN CN202211635437.3A patent/CN115990242A/zh active Pending
- 2014-02-28 CN CN202211634590.4A patent/CN115990241A/zh active Pending
- 2014-02-28 DK DK14756991.7T patent/DK2961420T3/da active
- 2014-02-28 EP EP19190165.1A patent/EP3626252A1/en not_active Withdrawn
- 2014-02-28 JP JP2015560377A patent/JP6518197B2/ja active Active
- 2014-02-28 WO PCT/US2014/019622 patent/WO2014134554A1/en not_active Ceased
- 2014-02-28 CA CA2916880A patent/CA2916880C/en active Active
- 2014-02-28 HU HUE14756991A patent/HUE046924T2/hu unknown
- 2014-02-28 ES ES14756991T patent/ES2750258T3/es active Active
- 2014-02-28 EP EP14756991.7A patent/EP2961420B1/en active Active
- 2014-02-28 CN CN201480022767.2A patent/CN105407906A/zh active Pending
-
2017
- 2017-06-19 US US15/626,255 patent/US11083771B2/en active Active
-
2019
- 2019-04-19 JP JP2019080101A patent/JP6918046B2/ja active Active
-
2020
- 2020-07-15 US US16/929,370 patent/US11083772B2/en active Active
-
2021
- 2021-02-10 JP JP2021019903A patent/JP7072692B2/ja active Active
- 2021-07-09 US US17/371,475 patent/US11771734B2/en active Active
-
2022
- 2022-05-10 JP JP2022077425A patent/JP7381652B2/ja active Active
-
2023
- 2023-08-23 US US18/454,319 patent/US12268724B2/en active Active
-
2025
- 2025-03-10 US US19/074,720 patent/US20260061023A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022116008A5 (https=) | ||
| JP2022046811A5 (https=) | ||
| JP2016511259A5 (https=) | ||
| Selman et al. | Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches | |
| Thiemermann et al. | Role of tumour necrosis factor in the induction of nitric oxide synthase in a rat model of endotoxin shock | |
| US7713924B2 (en) | Methods for treating conditions associated with the accumulation of excess extracellular matrix | |
| JP7175506B2 (ja) | 低血圧治療のための単独または併用使用されるアンギオテンシンｉｉ | |
| JP2016503397A5 (https=) | ||
| JP2010509258A (ja) | アデノシンアンタゴニストの使用 | |
| JP2003507418A5 (https=) | ||
| Gavras et al. | The angiotensin II type 1 receptor blocker losartan in clinical practice: a review | |
| Gheorghiade et al. | Review of randomized trials of digoxin therapy in patients with chronic heart failure | |
| Merolla et al. | Respiratory syncytial virus replication in human lung epithelial cells: inhibition by tumor necrosis factor alpha and interferon beta. | |
| KR102456270B1 (ko) | 비천연 아미노산 유도체를 함유하는 근감소증의 예방 또는 치료용 약학적 조성물 | |
| JP2016522196A5 (https=) | ||
| Badesch et al. | Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension | |
| US5972990A (en) | Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims | |
| Ye et al. | Inhibition of the P2X7 receptor prevents atrial proarrhythmic remodeling in experimental post-operative atrial fibrillation | |
| US20050124534A1 (en) | Methods for treating conditions associated with the accumulation of excess extracellular matrix | |
| JP2022549066A5 (https=) | ||
| JP2004536834A5 (https=) | ||
| Kaplan et al. | Vasopressin: new uses in critical care | |
| Páez Pereda et al. | Glucocorticoids Inhibit the Autoregulatory Induction of lnterleukin-1 in Monocytes after Endotoxin Stimulation. | |
| Neunteufl et al. | Endothelin receptor antagonists in cardiology clinical trials | |
| Pickering | The use of angiotensin converting enzyme inhibitors in combination with other antihypertensive agents |